4 completed, 1 active not recruiting. 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Active not recruiting 1 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow solanezumab: new trials by email Literature Review of solanezumab trials Research Report on solanezumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
Alzheimer Disease (5) · Dementia (2)
Eli Lilly and Company (3) · Washington University School of Medicine (2)
United States (4) · Australia (2) · Canada (2) · France (2) · Ireland (2) · Japan (2) · Puerto Rico (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Brazil (1) · Colombia (1) · Germany (1) · Italy (1) · Netherlands (1)
PMID 36110925, PMID 37017737, PMID 38683602, PMID 39974075, PMID 40120616, PMID 40985290
R01AG046179 (2), U01AG042791 (2), R01AG053267 (1), R56AG053267 (1), U01AG059798 (1)